Literature DB >> 23669229

Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho.

Hind Satti1, Megan M McLaughlin, Kwonjune J Seung.   

Abstract

Treating drug-resistant tuberculosis (DR-TB) is particularly challenging in high human immunodeficiency virus (HIV) prevalence settings. Neither antiretroviral resistance testing nor viral load monitoring is widely available in sub-Saharan Africa, and antiretroviral resistance can complicate the clinical management for DR-TB/HIV coinfected patients. We describe six cases of antiretroviral resistance in DR-TB patients with HIV coinfection in Lesotho. Two patients died before or immediately after antiretroviral resistance was detected by genotyping; the remaining four patients were switched to effective antiretroviral therapy (ART) regimens. Favorable DR-TB treatment outcomes in coinfected patients require successful management of their HIV infection, including treatment with an effective ART regimen. Coinfected patients undergoing DR-TB treatment may require closer monitoring of their response to ART, including routine viral load testing, to ensure that they receive an effective ART regimen concurrent with DR-TB treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669229      PMCID: PMC3748478          DOI: 10.4269/ajtmh.13-0046

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

Review 1.  2011 update of the drug resistance mutations in HIV-1.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Günthard; Roger Paredes; Deenan Pillay; Robert Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2011-11

2.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

Authors:  P Richard Harrigan; Robert S Hogg; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Justin Woodward; Chanson J Brumme; Zabrina L Brumme; Theresa Mo; Chris S Alexander; Julio S G Montaner
Journal:  J Infect Dis       Date:  2004-12-22       Impact factor: 5.226

3.  Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.

Authors:  K F Laserson; L E Thorpe; V Leimane; K Weyer; C D Mitnick; V Riekstina; E Zarovska; M L Rich; H S F Fraser; E Alarcón; J P Cegielski; M Grzemska; R Gupta; M Espinal
Journal:  Int J Tuberc Lung Dis       Date:  2005-06       Impact factor: 2.373

4.  CD4 cell counts in human immunodeficiency virus-negative patients with tuberculosis.

Authors:  B E Jones; M M Oo; E K Taikwel; D Qian; A Kumar; E R Maslow; P F Barnes
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

5.  Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

Authors:  Andrew Boulle; Gilles Van Cutsem; Karen Cohen; Katherine Hilderbrand; Shaheed Mathee; Musaed Abrahams; Eric Goemaere; David Coetzee; Gary Maartens
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

6.  Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda.

Authors:  Steven J Reynolds; Gertrude Nakigozi; Kevin Newell; Anthony Ndyanabo; Ronald Galiwongo; Iga Boaz; Thomas C Quinn; Ron Gray; Maria Wawer; David Serwadda
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

Review 7.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.

Authors:  Helen McIlleron; Graeme Meintjes; William J Burman; Gary Maartens
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

Review 8.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

9.  Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.

Authors:  Prema Gurumurthy; Geetha Ramachandran; A K Hemanth Kumar; S Rajasekaran; C Padmapriyadarsini; Soumya Swaminathan; P Venkatesan; L Sekar; S Kumar; O R Krishnarajasekhar; P Paramesh
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

10.  Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa.

Authors:  Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more
  3 in total

1.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

2.  Viral load for HIV treatment failure management: a report of eight drug-resistant tuberculosis cases co-infected with HIV requiring second-line antiretroviral treatment in Mumbai, India.

Authors:  Aristomo Andries; Mrinalini Das; Petros Isaakidis; Peter Saranchuk
Journal:  Am J Trop Med Hyg       Date:  2013-12       Impact factor: 2.345

3.  Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013.

Authors:  M Verdecchia; K Keus; S Blankley; D Vambe; C Ssonko; T Piening; E C Casas
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.